GlassScriptPhysician profile
Heena M Contractor
NPI 1518954973
$3,338.71
in general payments reported to CMS, 2019-2025
25 companies · $582 in 2025
The $582 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $249 · 2020: $230 · 2021: $343 · 2022: $497 · 2023: $551 · 2024: $888 · 2025: $582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,021.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,020.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $384.80 | 2021-2024 | Benlysta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $383.23 | 2019-2025 | Farxiga, Lokelma |
| Horizon Therapeutics Plc | $331.38 | 2019-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $323.09 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $296.42 | 2019-2025 | Jynarque |
| Ardelyx, INC. | $244.84 | 2024-2025 | Ibsrela |
| Vifor Pharma, INC. | $206.56 | 2019-2024 | Korsuva, Veltassa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.84 | 2019-2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $142.61 | 2021-2023 | Lupkynis |
| Medtronic, INC. | $106.37 | 2024 | Signia |
| Travere Therapeutics, INC. | $92.64 | 2023-2025 | |
| Amgen INC. | $83.01 | 2022-2025 | Krystexxa |
| Opko Pharmaceuticals, LLC | $81.73 | 2020-2025 | Rayaldee |
| Lilly USA, LLC | $64.77 | 2022-2023 | Mounjaro |
| Novartis Pharmaceuticals Corporation | $59.43 | 2024-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $53.32 | 2025 | Vafseo |
| Calliditas Therapeutics US INC. | $52.90 | 2023-2024 | Tarpeyo |
| Alexion Pharmaceuticals, INC. | $52.59 | 2023-2025 | Ultomiris |
| Lundbeck LLC | $43.09 | 2025 | Rexulti |
| Sanofi Pasteur INC. | $24.82 | 2022 | |
| Daiichi Sankyo INC. | $24.38 | 2022 | |
| Novo Nordisk INC | $23.06 | 2020 | |
| Neurocrine Biosciences, INC. | $19.75 | 2024 | Ingrezza |
| Cmp Pharma, INC. | $19.34 | 2021 | |
| Mallinckrodt Enterprises LLC | $18.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heena Contractor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.